Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17807
Title: | Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. | Austin Authors: | Jo, Helen E;Glaspole, Ian;Grainge, Christopher;Goh, Nicole S L ;Hopkins, Peter M A;Moodley, Yuben;Reynolds, Paul N;Chapman, Sally;Walters, E Haydn;Zappala, Christopher;Allan, Heather;Keir, Gregory J;Hayen, Andrew;Cooper, Wendy A;Mahar, Annabelle M;Ellis, Samantha;Macansh, Sacha;Corte, Tamera J | Affiliation: | Dept of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia Faculty of Medicine, University of Sydney, Sydney, Australia Dept of Allergy and Respiratory Medicine, The Alfred Hospital, Melbourne, Australia Faculty of Medicine, Monash University, Melbourne, Australia Dept of Respiratory Medicine, John Hunter Hospital, Newcastle, Australia Respiratory and Sleep Medicine School of Medicine, University of Queensland, Brisbane, Australia Dept of Respiratory Medicine, Fiona Stanley Hospital, Perth, Australia Dept of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, Australia University of Tasmania, Hobart, Australia Dept of Thoracic Medicine, Royal Brisbane & Women's Hospital, Brisbane, Australia Lung Foundation Australia, Brisbane, Australia Dept of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Australia Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia Dept of Radiology, The Alfred Hospital, Melbourne, Australia |
Issue Date: | Feb-2017 | Date: | 2017-02-23 | Publication information: | The European Respiratory Journal 2017; 49(2): 1601592 | Abstract: | The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17807 | DOI: | 10.1183/13993003.01592-2016 | ORCID: | 0000-0003-1183-2729 |
Journal: | The European Respiratory Journal | PubMed URL: | 28232409 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.